Physician profile
Amar Safdar
NPI 1982700837
$283,973.60
in general payments reported to CMS, 2019-2025
12 companies · $85K in 2025
The $85K reported for 2025 was more than what 99% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $21K · 2021: $345 · 2022: $762 · 2023: $70K · 2024: $60K · 2025: $85K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $151K · Travel and Lodging: $42K · Consulting Fee: $11K · Honoraria: $6,726 · Food and Beverage: $3,937 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150,967.25 |
| Travel and Lodging | $41,563.22 |
| Consulting Fee | $10,875.00 |
| Honoraria | $6,726.00 |
| Food and Beverage | $3,936.53 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Melinta Therapeutics, LLC | $114,054.50 | 2023-2025 | Rezzayo |
| Merck Sharp & Dohme LLC | $104,300.16 | 2019-2025 | Zerbaxa |
| Insmed, INC. | $30,665.90 | 2019-2021 | |
| Allergan, INC. | $14,330.65 | 2020 | |
| La Jolla Pharmaceutical Company | $8,259.53 | 2021-2024 | Xacduro, Xerava |
| Glaxosmithkline, LLC. | $8,125.00 | 2023-2024 | |
| Tetraphase Pharmaceuticals, INC. | $2,070.07 | 2019 | |
| Invivyd INC | $1,750.00 | 2024 | Pemgarda |
| Abbvie INC. | $322.17 | 2022-2024 | Dalvance |
| United Therapeutics Corporation | $67.24 | 2021 | |
| Astellas Pharma US INC | $16.26 | 2019 | |
| Celltrion, INC. | $12.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amar Safdar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.